Company name: Vitality Biopharma (acquired in 2016)
Description: Developer and distributor of cannabinoid pharmaceuticals. The company’s cannabinoid pharmaceuticals are developed from medical cannabis and are medications or compounds that, after administration, are converted within the body into a pharmacologically active drug, which already has a long history of clinical investigation and use, enabling physicians to treat serious neurological and inflammatory disorders.
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
City: Los Angeles
Country: United States
Start up capital raised (USD Million):
Business status: Generating Revenue
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Earnings before interest, tax, depreciation and amortization (EBITDA):
Financing Status: The company was acquired by Vitality Biopharma (formerly known as Stevia First) through a reverse merger, resulting in the combined entity trading on the OTC Stock Exchange under the ticker symbol VBIO on July 15, 2016.
Number of active investors:
Profile last updated: 08-Sep-2018
Last known valuation:
Last known valuation date: